Trumps new crown therapy is also being studied by A-share companies

 Trumps new crown therapy is also being studied by A-share companies

On October 3, Sean Conley said that trump, who is undergoing treatment with a new crown, is now in remission and in excellent condition on the morning of the 3rd.

Antibody cocktail therapy is not a new treatment idea, its history can be traced back to plasma therapy more than 100 years ago.

In 1890, German scientist Emil von belling and Japanese scientist kitazaki Saburo immunized animals with detoxified diphtheria toxin (a protein released by Diphtheria Bacillus) or tetanus toxin (a protein released by tetanus bacillus), a substance that can neutralize the toxin was found in the animal serum, which was called antitoxin (the antibody we now call it), It can prevent the pathogenicity of diphtheria or tetanus toxin.

On December 16 of the same year, Charles Richter, a French bacteriologist and pathologist, prepared serum from the blood of dogs injected with Mycobacterium tuberculosis. He tried to use dog serum injection for the first time in Paris to treat tuberculosis, and achieved success, marking that human can use serum or plasma to treat infectious diseases.

In recent years, plasma therapy has been gradually used in the trial treatment of viral infectious diseases. In many emergency and major outbreaks, such as SARS, H5N1, h7n9 avian influenza, Middle East respiratory syndrome (mers), Ebola epidemic, etc., plasma therapy in convalescent period has been seen.

Based on this, modern medicine upgrades plasma therapy, that is, instead of centrifuging the plasma of the convalescent patients and injecting the upper serum to the patients, it uses neutralizing antibodies screened and prepared artificially.

Novel coronavirus pneumonia has also been taken seriously in the fight against the new crown pneumonia, and many countries, including China, are pushing the therapy.

On September 29, Zaiyuan pharmaceutical company released the early results of clinical trials of the treatment, Xinhua reported. The results showed that this treatment reduced the viral load and shortened the time taken for non hospitalized patients with new crown to relieve symptoms. For patients who did not produce effective immune response to new coronavirus, the effect of this therapy was the most obvious.

With its leading performance in the field of neutralization antibody, the share price of Zaiyuan Pharmaceutical Co., Ltd. has risen greatly this year, with the largest increase of more than 80%.

Novel coronavirus pneumonia is expected to become a specific drug for treating new crown pneumonia. Considering the development time, R & D success rate, drug specificity and safety, the hope is that the vaccine prevention and combination of antibody therapy will be the end of the new crown disease.

Among domestic enterprises, js016, brii-196 and brii-198, mw33 of Maiwei biology and scta01 of Shenzhou cell, which are jointly developed by Junshi biology and Institute of Microbiology, Chinese Academy of Sciences, have entered the clinical trial stage. Junshi is in the leading position.

On July 13, Junshi bio announced that the recombinant human anti sars-cov-2 monoclonal antibody injection (product code js016) jointly developed by the company and the Institute of Microbiology, Chinese Academy of Sciences, has completed the administration of all subjects in Chinas phase I clinical trial. Js016 is the first neutralizing antibody against new coronavirus in China and the second in the world.

The candidate drug was favored by Lilly, and the two sides reached an agreement on May 4 this year, in which Lilly bought out the clinical development and commercialization rights and interests of js016 outside the Greater China region at a price of up to 255 million US dollars.

However, compared with regenerant pharmaceutical company, the stock price performance of Junshi bio-u after listing was ordinary.

Editor: Qiu Jiangs extended reading: Trumps diagnosis of cold water from non agriculture: huge uncertainty sweeping the globe black swan? Global capital market earthquake institutions cant hold back October surprise! FTSE Chinas A50 rises against the trend in global stock market_ NF5619

Editor: Qiu Jiang